KJ
Ken Joseph Portfolio
Invests via Braidwel LLP | Managed by Alex Karnal, Brian Kreiter
Invests via Braidwel LLP
Managed by Alex Karnal, Brian Kreiter
Automatically Tracked
Ken Joseph Profile
Ken Joseph is a seasoned operating executive with extensive experience in the financial technology sector. His career trajectory includes significant leadership roles where he successfully scaled organizations and drove product innovations that enhanced market competitiveness. Recognized for his adeptness in navigating complex regulatory environments, he has effectively guided companies through transformative growth phases while fostering strong stakeholder relationships. Ken's deep understanding of both technical developments and business strategy positions him as a pivotal figure in enhancing operational efficiencies and executing growth initiatives within the capital markets landscape.
Ken Joseph is a seasoned operating executive with extensive experience in the financial technology sector. His career trajectory includes significant leadership roles where he successfully scaled organizations and drove product innovations that enhanced market competitiveness. Recognized for his adeptness in navigating complex regulatory environments, he has effectively guided companies through transformative growth phases while fostering strong stakeholder relationships. Ken's deep understanding of both technical developments and business strategy positions him as a pivotal figure in enhancing operational efficiencies and executing growth initiatives within the capital markets landscape.
Investment Philosophy & Strategy
Innovation in the financial technology arena remains pivotal, and Ken Joseph exemplifies a leadership approach that champions transformative growth. Drawing from his extensive operating experience, he focuses on strategic scalability while prioritizing cutting-edge product development to enhance market presence. His ability to blend technical acumen with sharp business insights fosters an environment where operational efficiency thrives alongside competitive innovation. By forging robust relationships with stakeholders, Ken ensures that organizational growth aligns seamlessly with evolving market dynamics, positioning ventures for sustainable success.
Innovation in the financial technology arena remains pivotal, and Ken Joseph exemplifies a leadership approach that champions transformative growth. Drawing from his extensive operating experience, he focuses on strategic scalability while prioritizing cutting-edge product development to enhance market presence. His ability to blend technical acumen with sharp business insights fosters an environment where operational efficiency thrives alongside competitive innovation. By forging robust relationships with stakeholders, Ken ensures that organizational growth aligns seamlessly with evolving market dynamics, positioning ventures for sustainable success.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
25%
Gain -0.04%
Monthly
0.97%
Yearly
12.25%
Drawdown
25.8%
$3.23B
Equity
Holdings
$3.23B
Investment
$2.77B
$1.3B
Profit -$1.61M
Realized
$838.55M
Unrealized
$457.99M
Dividends
$2.91M
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
-0.04%
Profit
-$1.61M
Win %
64%
This Week
Compared To Last Week
Gain
-0.27%
Profit
-$8.75M
Win %
64%
This Month
Compared to last month
Gain
-1.39%
Profit
-$45.48M
Win %
64%
This Year
Compared to last year
Gain
3.69%
Profit
$114.98M
Win %
64%
KPTI Karyopharm Therapeutics Inc.
+10.44%
+$285,167.8 
NRIX Nurix Therapeutics Inc.
+5.63%
+$2.09M 
DNTH Dianthus Therapeutics Inc.
+3.69%
+$3.59M 
GLUE Monte Rosa Therapeutics, Inc.
+3.27%
+$531,056.96 
XFOR X4 Pharmaceuticals Inc.
+2.71%
+$353,734.92 
HROW Harrow Inc.
+2.5%
+$277,573.54 
KYMR Kymera Therapeutics Inc.
+2.02%
+$763,155.12 
SYRE Spyre Therapeutics, Inc.
+1.91%
+$2.52M 
SRZN Surrozen, Inc.
+1.41%
+$155,100 
EWTX Edgewise Therapeutics, Inc.
+1.4%
+$2.47M 
CLDX Celldex Therapeutics Inc.
+1.2%
+$668,919.24 
DYN Dyne Therapeutics Inc.
+1%
+$266,099.22 
EOLS Evolus Inc.
+0.92%
+$186,312.54 
VERA Vera Therapeutics Inc.
+0.89%
+$235,736.5 
ZURA Zura Bio Ltd.
+0.84%
+$95,411.67 
CVS CVS Health Corporation
+0.75%
+$423,150 
APGE Apogee Therapeutics Inc.
+0.69%
+$356,196.5 
KRYS Krystal Biotech Inc.
+0.56%
+$360,467.34 
RLMD Relmada Therapeutics Inc.
+0.55%
+$56,328.35 
DRUG Bright Minds Biosciences Inc.
+0.54%
+$107,038.14 
XENE Xenon Pharmaceuticals Inc.
+0.52%
+$492,770.52 
TECX Tectonic Therapeutic Inc.
+0.46%
+$125,215.74 
BIIB Biogen Inc.
+0.46%
+$105,864.34 
BMRN Biomarin Pharmaceutical Inc.
+0.39%
+$129,326.8 
CGON CG Oncology, Inc.
+0.36%
+$392,819.91 
KIDS OrthoPediatrics Corp.
+0.32%
+$62,721.09 
ENGN enGene Therapeutics Inc.
+0.3%
+$15,656.59 
FULC Fulcrum Therapeutics Inc.
+0.28%
+$30,612.22 
ARGX argenx SE American Depositary Receipt
+0.24%
+$66,665.05 
KOD Kodiak Sciences Inc.
+0.18%
+$124,367.28 
XNCR Xencor Inc.
+0.11%
+$5,877.32 
40131MAD1
0%
$0 
450056AB2
0%
$0 
46333XAH1
0%
$0 
64049MAB6
0%
$0 
759916AD1
0%
$0 
CMPX Compass Therapeutics Inc.
0%
$0 
RAPT Rapt Therapeutics, Inc.
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
VTYX Ventyx Biosciences, Inc.
0%
$0 
MBX MBX Biosciences, Inc.
-7.46%
-$2.83M 
TMDX TransMedics Group Inc.
-2.8%
-$649,602.46 
ISRG Intuitive Surgical, Inc.
-2.11%
-$725,727.9 
MRVI Maravai Lifesciences Holdings Inc.
-2.01%
-$876,259.81 
BLLN BillionToOne, Inc.
-1.96%
-$97,500 
NEO NeoGenomics Inc.
-1.79%
-$949,724.2 
ILMN Illumina, Inc.
-1.25%
-$562,537.88 
NTRA NATERA INC (Common Stock) – ticker 45E
-1.13%
-$276,520 
ALGN Align Technology, Inc.
-1.13%
-$758,197.96 
ADPT Adaptive Biotechnologies Corporation
-1.09%
-$63,958.15 
BTSG BrightSpring Health Services, Inc.
-1.01%
-$763,748.52 
RGEN Repligen Corporation
-0.99%
-$107,963.62 
CDNA CareDx Inc.
-0.96%
-$361,430.16 
LEGN Legend Biotech Corporation American Depositary Shares
-0.95%
-$448,248.43 
CAI Caris Life Sciences, Inc.
-0.89%
-$1.25M 
ICLR ICON plc
-0.81%
-$89,511.4 
IRTC Irhythm Technologies Inc.
-0.78%
-$191,633.09 
NBIX Neurocrine Biosciences Inc.
-0.74%
-$909,356.14 
GKOS Glaukos Corporation
-0.72%
-$829,781.1 
GRAL Grail, Inc.
-0.64%
-$54,960.68 
TMO Thermo Fisher Scientific Inc.
-0.64%
-$243,789.5 
DHR Danaher Corporation
-0.43%
-$92,217.06 
HNGE Hinge Health Inc.
-0.42%
-$358,771.33 
LUNG Pulmonx Corporation
-0.3%
-$3,160.67 
INSP Inspire Medical Systems, Inc.
-0.28%
-$64,906.8 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
-0.25%
-$218,832 
NUVL Nuvalent, Inc.
-0.15%
-$147,853.08 
CSTL Castle Biosciences, Inc.
-0.14%
-$5,315.49 
PEN Penumbra Inc.
-0.12%
-$41,857.76 
ORKA Oruka Therapeutics, Inc.
-0.11%
-$6,130.68 
ACAD Acadia Pharmaceuticals Inc.
-0.05%
-$20,320.21 
KNSA Kiniksa Pharmaceuticals International, plc
-0.04%
-$6,276.46 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 788 | Longs Won 370/788 46% | Profit Factor 2.15 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $13.86M |
| Average Win $6.56M | Best Trade (Mar 31) $294.48M | Sharpe Ratio -170.09 |
| Average Loss -$2.71M | Worst Trade (Jun 10) -$69.94M | Z-Score -0.79 (57.04%) |
| Commissions $0 | Avg. Trade Length 10m 4w 1d | Expectancy $1.65M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.3% |
| Consecutive Losing Trades | 1,193 | 1,074 | 955 | 835 | 716 | 597 | 477 | 358 | 239 | 119 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
